Why the study?
How should low-molecular-weight heparin be dosed for bridge therapy in obese patients and patients with renal dysfunction?
Population
Obese patients and patients with renal dysfunction requiring bridging anticoagulation therapy or short-term…
Comparison
Low-molecular-weight heparin, specifically… vs Normal-weight individuals (for obesity studies)
Design
Review
Authors
Loading...
May support total-body-weight LMWH dosing in obese patients for bridging; extends renal accumulation data but remains hypothesis-generating.
How should low-molecular-weight heparin be dosed for bridge therapy in obese patients and patients with renal dysfunction?
For LMWH bridge therapy, obese patients (90-150 kg) should receive dosages based on total body weight, while enoxaparin should be avoided in patients with CrCl ≤30 ml/min.
George-Phillips et al. (2006) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: